Venmax drugs & pharmaceuticals Limited has announced a significant leadership change with the promotion of Mr. Venkata Rao Sadhanala from Whole Time Director to Managing Director. The Board of Directors approved this designation change during their meeting held on March 11, 2026, following recommendations from the Nomination and Remuneration Committee.

Appointment Details and Terms

The new appointment carries a five-year term, commencing March 11, 2026, and concluding on March 10, 2031. However, the appointment remains subject to approval from the company's shareholders at the next General Meeting.

Leadership Profile and Experience

Mr. Venkata Rao Sadhanala (DIN: 02906370) brings substantial industry expertise to his enhanced role. As a qualified Chartered Accountant and Company Secretary, he possesses over three decades of experience spanning multiple sectors including banking, finance, FMCG, and pharmaceutical industries.

His professional background encompasses:

• Extensive experience in project finance and corporate strategies
• Expertise in mergers and acquisitions
• Senior leadership positions at Vanta Bioscience Ltd and Synergy Castings Ltd
• Deep understanding of pharmaceutical industry operations

Board Meeting Proceedings

The Board Meeting that approved this designation change commenced at 4:30 PM and concluded at 5:30 PM on March 11, 2026. The company has fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

Venmax Drugs & Pharmaceuticals Limited has provided comprehensive details as required under SEBI regulations, ensuring full transparency regarding the leadership change. The appointment follows proper corporate governance procedures, including committee recommendations and pending shareholder approval, demonstrating the company's commitment to regulatory compliance and stakeholder engagement.

Venmax Drugs & Pharmaceuticals Limited has submitted its unaudited standalone financial results for Q3FY26 along with its quarterly compliance statement confirming no deviation in preferential issue fund utilization. The company reported total revenue of ₹162.06 lakhs for the quarter ended December 31, 2025, marking a significant turnaround from the previous year.

Q3FY26 Financial Performance

The company demonstrated strong operational recovery with substantial revenue growth and return to profitability. The financial results were approved by the Board of Directors on February 7, 2026, following audit committee review.

Nine Months Performance

For the nine months ended December 31, 2025, the company achieved total revenue of ₹414.93 lakhs compared to ₹50.44 lakhs in the corresponding period of the previous year, representing a growth of over 720%.

Fund Utilization Compliance

Simultaneously, the company filed its quarterly statement confirming no deviation in the utilization of funds raised through its preferential issue. The fund raising exercise was completed on March 20, 2025, with total amount of ₹20.05 crores to be raised.

The proceeds were allocated for working capital (₹10 crores) and general corporate purposes including business acquisition (₹10.05 crores), with ₹3.79 crores and ₹0.19 crores utilized respectively, showing no deviation from stated objectives.

Corporate Governance

Both the financial results and fund utilization statement were reviewed by the Audit Committee and approved by the Board of Directors on February 7, 2026. The statutory auditors PPKG & Co Chartered Accountants conducted a limited review of the financial results and expressed an unmodified conclusion. The company confirmed compliance with Regulation 33 and Regulation 32 of SEBI (LODR) Regulations, 2015, demonstrating strong governance practices and transparent disclosure to stakeholders.